Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Leukemia and Lymphoma

Volumn 56, Issue 7, 2015, Pages 2067-2074

  Jung, Chul Won ^a   Shih, Lee Yung ^b   Xiao, Zhijian ^c   Jie, Jin ^d   Hou, Hsin An ^e   Du, Xin ^f   Wang, Ming Chung ^g   Park, Seonyang ^h   Eom, Ki Seong ⁱ   Oritani, Kenji ^j   Okamoto, Shinichiro ^k   Tauchi, Tetsuzo ^l   Kim, Jin Seok ^m   Zhou, Daobin ⁿ   Saito, Shigeki ^o   Li, Junmin ^p   Handa, Hiroshi ^q   Jianyong, Li ^r   Ohishi, Kohshi ^s   Hou, Ming ^t   Depei, Wu ^u   Takenaka, Katsuto ^v   Liu, Ting ^w   Hu, Yu ^x   Amagasaki, Taro ^y   Ito, Kazuo ^y   Gopalakrishna, Prashanth ^z   Akashi, Koichi ^v   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^h Seoul National University Hospital   (South Korea)

ⁱ The Catholic University of Korea   (South Korea)

^j OSAKA UNIVERSITY HOSPITAL   (Japan)

^k KEIO UNIVERSITY HOSPITAL   (Japan)

^l TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^m Yonsei University College of Medicine   (South Korea)

ⁿ PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^o NAGOYA UNIVERSITY HOSPITAL   (Japan)

^p SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^q GUNMA UNIVERSITY HOSPITAL   (Japan)

^r THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^s MIE UNIVERSITY HOSPITAL   (Japan)

^t SHANDONG UNIVERSITY   (China)

^u SOOCHOW UNIVERSITY   (China)

^v KYUSHU UNIVERSITY HOSPITAL   (Japan)

^w SICHUAN UNIVERSITY   (China)

^x HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^y NOVARTIS PHARMA K K   (Japan)

^z NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Asian patient population; JAK1 JAK2 inhibitor; Myelofibrosis; Phase 2

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; RUXOLITINIB; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEPATORENAL SYNDROME; HERPES ZOSTER; HUMAN; KIDNEY FAILURE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOFIBROSIS; MYELOFIBROSIS SYMPTOM ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RHINOPHARYNGITIS; SIDE EFFECT; SPLEEN SIZE; SPLENOMEGALY; SYMPTOM ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PRIMARY MYELOFIBROSIS; PROGNOSIS; QUALITY OF LIFE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; NEOPLASM STAGING; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY OF LIFE;

EID: 84938117732     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.969260     Document Type: Article

References (19)

1. Barosi G, Rosti V Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother 2011;12:1597-1611.
2. Mesa RA, Green A, Barosi G, et al. MPN-associated myelofibrosis (MPN-MF). LeukRes 2011;35:12-13.
3. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76.
4. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
5. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol 2013;6:79.
6. VerstovsekS, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
7. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
8. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
9. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013; 98: 1865-1871.
10. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Vol 2. Lyon: IARC;2008.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
12. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement:performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011;117:4869-4877.
13. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-1203.
14. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
15. BarosiG,BergamaschiG,MarchettiM,et al. JAK2V617Fmutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-4036.
16. GuglielmelliP, BarosiG, SpecchiaG, et al. Identificationofpatients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009;114:1477-1483.
17. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.
18. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008;83:491-497.
19. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233-245.